Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Interleukin-2 based therapy for kidney cancer.

Janice P Dutcher¹

¹Our Lady of Mercy Cancer Center, New York Medical College, USA.

Cancer Treatment and Research

|December 4, 2003

Summary

High-dose interleukin-2 (IL-2) therapy is the standard for metastatic renal cell cancer, but new regimens are needed to improve response rates beyond 20% and explore subtype-specific immunotherapy responses.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The American Federation for Medical Research maintains commitment to decades of support of vaccine and vaccination research to improve public health.

Journal of investigative medicine : the official publication of the American Federation for Clinical Research·2025

Same author

Families with multiple individuals with acute leukemia in their pedigrees.

Journal of investigative medicine : the official publication of the American Federation for Clinical Research·2024

Same author

Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2024

Same author

Families with non-Hodgkin lymphoma and plasma cell dyscrasias in their pedigrees.

Journal of investigative medicine : the official publication of the American Federation for Clinical Research·2023

Same author

Results From a Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features: ECOG-ACRIN E1808.

Clinical genitourinary cancer·2023

Same author

Adjuvant therapy in patients with sarcomatoid renal cell carcinoma: post hoc analysis from Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) E2805.

BJU international·2021

Area of Science:

Oncology
Immunotherapy
Renal Cell Carcinoma Research

Background:

Interleukin-2 (IL-2) based therapy is a cornerstone in treating metastatic renal cell cancer.
Current IL-2 regimens achieve a mean response rate of approximately 20%, indicating a need for improved treatment strategies.

Purpose of the Study:

To review current IL-2 based therapies for metastatic renal cell cancer.
To identify areas for improvement in IL-2 based treatment regimens.
To explore potential differences in immunotherapy response among renal cell cancer histologic subtypes.

Main Methods:

Review of existing studies on IL-2 based therapy for metastatic renal cell cancer.
Analysis of response rates and variations in treatment regimens.
Discussion of potential subtype-specific responses to immunotherapy.

Main Results:

High-dose IL-2 remains the established standard regimen for comparison.
Numerous variations in IL-2 based therapy regimens exist.
Further research is ongoing to explore histologic subtype differences in treatment response.

Conclusions:

Optimizing IL-2 based regimens to exceed a 20% response rate is an ongoing challenge.
Investigating histologic subtypes may reveal differential responses to immunotherapy.
Simplicity and institutional feasibility are key considerations when selecting IL-2 based regimens.

Related Experiment Videos